Citations

Clear

3942 citation(s) found for "To, Van".

Sacrificial Bioprinting of a Mammary Ductal Carcinoma Model
Duchamp, Margaux , Liu, Tingting , Genderen, Anne Metje van , Kappings, Vanessa, Öklü, Rahmi , Ellisen, Leif W. , Oklu, Rahmi , Zhang, Yu Shrike

Mayo Clinic

Biotechnology Journal | April 9, 2019 | Volume: 14 | Issue: 10 | Pages: No page available

10.1002/biot.201700703 | PMID 30963705 Get It

Cancer tissue engineering has remained challenging due to the limitations of the conventional biofabrication techniques to model the complex tumor microenvironment. Here, the utilization of a sacrificial bioprinting strategy is reported to generate the biomimetic mammary duct‐like structure within a hydrogel matrix, which is further populated with breast cancer cells, to model the genesis of ductal carcinoma and its subsequent outward invasion. This bioprinted mammary ductal carcinoma model provides a proof‐of‐concept demonstration of the value of using the sacrificial bioprinting technique for engineering biologically relevant cancer models, which may be possibly extended to other cancer types where duct‐like structures are involved.
White matter hyperintensities in vascular contributions to cognitive impairment and dementia (VCID): Knowledge gaps and opportunities
Alber, Jessica , Alladi, Suvarna , Barton, David A., Bell, Joanne M., Berman, Sara E., Biessels, Geert Jan , Bos, Isabelle , Bowman, Gene L. , Brai, Emanuele , Callahan, Brandy L. , Corriveau, Roderick A. , Fossati, Silvia , Gottesman, Rebecca F. , Gustafson, Deborah , Hachinski, Vladimir , Hayden, Kathleen M. , Helman, Alex M., Hughes, Timothy M. , Isaacs, Jeremy D. , Jefferson, Angela L. , Kern, Silke , Kwon, Jay C., Lee, Athene , Lockhart, Samuel N. , Murray, Anne M. , Osborn, Katie E. , Price, Brittani R. , Rhodius‐Meester, Hanneke , Rondeau, Jacqueline A., Rosen, Allyson , Scholtzova, Henrieta , Shaaban, C. Elizabeth , Silva, Nárlon Cássio Boa Sorte , Snyder, Heather M. , Swardfager, Walter , Troen, Aron M. , Vemuri, Prashanthi , Wallin, Anders , Wellington, Cheryl L. , Xie, Sharon X. , Hainsworth, Atticus H. , Vemuri, Prashanthi , Gottesman, Rebecca F , Hainsworth, Atticus H , Bae, Hee‐Joon , Beckett, Laurel , Biessels, Geert Jan , Black, Sandra E. , Brickman, Adam M. , Johnson, Sterling C. , Kapasi, Alifiya , Kukolja, Juraj , Power, Melinda C. , Rosene, Douglas L , Schneider, Julie A. , Veluw, Susanne J. van , Wilcock, Donna M.

Mayo Clinic

Alzheimer's & Dementia: Translational Research & Clinical Interventions | April 8, 2019 | Volume: 5 | Issue: 1 | Pages: 107-117

10.1016/j.trci.2019.02.001 | PMID 31011621 Get It

Abstract White matter hyperintensities (WMHs) are frequently seen on brain magnetic resonance imaging scans of older people. Usually interpreted clinically as a surrogate for cerebral small vessel disease, WMHs are associated with increased likelihood of cognitive impairment and dementia (including Alzheimer's disease [AD]). WMHs are also seen in cognitively healthy people. In this collaboration of academic, clinical, and pharmaceutical industry perspectives, we identify outstanding questions about WMHs and their relation to cognition, dementia, and AD. What molecular and cellular changes underlie WMHs? What are the neuropathological correlates of WMHs? To what extent are demyelination and inflammation present? Is it helpful to subdivide into periventricular and subcortical WMHs? What do WMHs signify in people diagnosed with AD? What are the risk factors for developing WMHs? What preventive and therapeutic strategies target WMHs? Answering these questions will improve prevention and treatment of WMHs and dementia.
Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies
Laubach, Jacob P. , Gutierrez, Maria Asunción Echeveste, Grząśko, Norbert , Miguel, Jesús F. San , Kumar, Shaji , Labotka, Richard, Lu, Vickie, Berg, Deborah, Byrne, Catriona , Teng, Zhaoyang , Liu, Guohui , Velde, Helgi van de , Richardson, Paul G. , Dimopoulos, Meletios A , San-Miguel, Jesus , Dimopoulos, Meletios Α. , Hofmeister, Craig C. , Richardson, Paul Gerard Guy

Mayo Clinic

European Journal of Haematology | April 3, 2019 | Volume: 102 | Issue: 6 | Pages: 494-503

10.1111/ejh.13231 | PMID 30943323 Get It

AbstractObjectivesTo evaluate the safety and efficacy of maintenance therapy with the oral proteasome inhibitor ixazomib in patients with newly diagnosed multiple myeloma (NDMM) not undergoing transplantation.MethodsData were pooled from four NDMM phase I/II studies; patients received induction therapy with once‐ or twice‐weekly ixazomib plus lenalidomide‐dexamethasone (IRd), melphalan‐prednisone (IMP), or cyclophosphamide‐dexamethasone (ICd), followed by single‐agent ixazomib maintenance, given at the last tolerated dose during induction, until disease progression, death, or unacceptable toxicity.ResultsA total of 121 patients achieved stable disease or better after induction (weekly IRd, n = 25; twice‐weekly IRd, n = 18; weekly or twice‐weekly IMP, n = 35; weekly ICd, n = 43) and received ≥ 1 dose of ixazomib maintenance. Grade ≥ 3 drug‐related adverse events occurred in 24% of patients during maintenance; each event was reported in ≤2% of patients. Rates of complete response were 22% after induction and 35% after maintenance. A total of 28 patients (23%) improved their response during maintenance.ConclusionsIxazomib maintenance following ixazomib‐based induction is associated with deepening of responses and a positive safety profile with no cumulative toxicity in patients with NDMM not undergoing transplantation, suggesting that ixazomib is feasible for long‐term administration. Phase III investigation of ixazomib maintenance is ongoing.
Expansile Traumatic Neuroma of the Intratemporal Facial Nerve
Feng, Yening , Patel, Neil , Burrows, Anthony M. , Lane, John I. , Carlson, Matthew L. , Raghunathan, Aditya , Gompel, Jamie J. Van

Mayo Clinic

Journal of Neurological Surgery Reports | April 1, 2019 | Volume: 80 | Issue: 01 | Pages: e10-e13

10.1055/s-0039-1685212 | PMID 30941279 Get It

Objectives To present a rare case of traumatic facial neuroma involving the geniculate ganglion and review relevant literature. Patient Thirty-year-old man. Intervention Microsurgical resection via combined mastoid-middle fossa approach with great auricular nerve interpositional graft. Main Outcome Measures Patient demographics and pre- and postoperative facial nerve function. Results A 30-year-old man with a reported history of prior Bell's palsy developed progressive complete (House–Brackmann VI) right facial paralysis following blunt trauma. Imaging was strongly suggestive of a geniculate ganglion hemangioma. As the patient had no spontaneous improvement in his poor facial function over the course of 9 months, he underwent resection of the facial nerve lesion with great auricular nerve graft interposition via a combined mastoid-middle fossa approach. Histopathology demonstrated disorganized fascicles, with axonal clustering reminiscent of sprouting/regeneration following trauma. No cellular proliferation or vascular malformation was present. Conclusion Traumatic facial nerve neuromas can occur following temporal bone trauma and can closely mimic primary facial nerve tumors. Akin to the management of geniculate ganglion hemangioma and schwannoma, preoperative facial function largely dictates if and when surgery should be pursued.
Breaking tolerance with engineered class I antigen-presenting molecules
Parks, Christopher A. , Henning, Kalli R., Hansen, Michael J. , Keulen, Virginia P. Van , Reed, Brendan , Schrum, Adam G. , Gil, Diana , Kranz, David M. , Bordner, Andrew J., Barry, Michael A. , Pease, Larry R. , Pavelko, Kevin D. , Reed, Brendan K, Schrum, Adam G , Barry, Michael A , Stone, Jennifer D.

Mayo Clinic

Proceedings of the National Academy of Sciences | April 1, 2019 | Volume: 116 | Issue: 8 | Pages: 3136-3145

10.1073/pnas.1807465116 | PMID 30728302 Get It

Significance Provision of sufficient activating signals can drive self-tolerant T cells to cross-react on self-peptide-MHC in a breakdown of tolerance. This approach has been applied in the development of heteroclitic peptide vaccines, which retain sufficient similarity to self to allow reactivation of effector cells on unaltered self-epitopes but require detailed knowledge about the behavior of individual altered self-peptide antigens. We designed altered-self MHC mutant antigen-presenting molecules to drive CTL capable of cross-reacting on self-peptide-MHC and demonstrate the breaking of self-tolerance to defined and undefined self-antigens. These findings bear particular importance in the field of cancer immunotherapy in which breaking tolerance to weakly antigenic cancer-associated antigens is fundamental to vaccination strategies.
Computed Tomography–Based Indexed Aortic Annulus Size to Predict Prosthesis-Patient Mismatch
Head, Stuart J., Reardon, Michael J. , Deeb, G. Michael, Popma, Jeffrey J. , Gleason, Thomas G. , Williams, Mathew , Radhakrishnan, Sam, Oh, Jae K. , Chang, Yanping, Boulware, Michael J., Investigators, for the SURTAVI, Reardon, Michael J , Deeb, G. Michael , Mieghem, Nicolas M. Van , Fremes, Stephen E. , Kappetein, A. Pieter , Investigators, for the SURTAVI, Williams, Mathew

Mayo Clinic

Circulation: Cardiovascular Interventions | April 1, 2019 | Volume: 12 | Issue: 4 | Pages: No page available

10.1161/circinterventions.118.007396 | PMID 30929507 Get It

Background: Hemodynamic performance of prostheses after transcatheter aortic valve replacement (TAVR) is generally better than after surgical aortic valve replacement (SAVR), especially in patients with a small native annulus size. However, it remains unclear whether differences are consistent for patients with a different propensity for developing prosthesis-patient mismatch (PPM), considering annulus size and body size of patients. Methods and Results: The SURTAVI trial (Surgical Replacement and Transcatheter Aortic Implantation) compared TAVR using a self-expandable valve with SAVR in intermediate-risk patients. Multidetector computed tomography–based aortic annulus size consisted of the perimeter-derived diameter, which was divided by body surface area to produce an indexed annulus size. Patients were categorized into a small (9–12 mm/m 2 ), medium (>12–14 mm/m 2 ), and large (>14–18 mm/m 2 ) group according to indexed annulus size. We compared TAVR and SAVR for PPM, hemodynamics, and clinical, and functional outcomes through 1-year follow-up within the size groups. Patients who underwent TAVR received a larger prosthesis with increasing indexed annulus size ( P <0.001), while there was no difference in prosthesis size in patients who underwent SAVR ( P =0.74). Patients in all size groups had significantly larger indexed effective orifice area and lower mean gradients at discharge after TAVR versus SAVR. Rates of PPM were significantly lower with TAVR versus SAVR in all groups ( P <0.001) and declined with larger indexed annulus sizes with both TAVR ( P =0.04) and SAVR ( P =0.03). Indexed annulus size was an independent predictor of PPM after TAVR and SAVR. Clinical outcomes were comparable between TAVR and SAVR across all groups, apart from a significantly higher rate of reintervention after TAVR versus SAVR in the large indexed annulus size group (2.5% versus 0%; P =0.01) but without significant interaction ( P int =0.81). Conclusions: Rates of PPM were significantly lower after TAVR than after SAVR across all groups of indexed annulus size, reflecting better hemodynamic performance of transcatheter versus surgical valves, irrespective of the propensity to develop PPM. More attention should be directed to prevention of PPM after SAVR. This information should be considered by the Heart Team to recommend a specific procedure or valve. Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT01586910.
Cystic Fibrosis Transmembrane Conductance Regulator Genotype, Not Circulating Catecholamines, Influences Cardiovascular Function in Patients with Cystic Fibrosis
Bisch, Alexander L, Wheatley, Courtney M. , Baker, Sarah E. , Peitzman, Elizabeth R. , Iterson, Erik H. Van , Laguna, Theresa A. , Snyder, Eric M., Van Iterson, Erik H , Baker, Sarah E , Morgan, Wayne J.

Mayo Clinic

Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine | March 29, 2019 | Volume: 13 | Issue: No issue available | Pages: No page available

10.1177/1179548419835788 | PMID 30956528 Get It

Background: Cystic fibrosis (CF) is a genetic disease affecting multiple organ systems of the body and is characterized by mutation in the gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR). Previous work has shown that a single dose of aβ-agonist increases cardiac output (Q) and stroke volume (SV) and decreases systemic vascular resistance (SVR) in healthy subjects. This effect is attenuated in patients with CF; however, the mechanism is unknown. Potential explanations for this decreased cardiovascular response to a β-agonist in CF include inherent cardiovascular deficits secondary to the CFTR mutation, receptor desensitization from prolonged β-agonist use as part of clinical care, or inhibited drug delivery to the bloodstream due to mucus buildup in the lungs. This study sought to determine the effects of endogenous epinephrine (EPI) and norepinephrine (NE) on cardiovascular function in CF and to evaluate the relationship between cardiovascular function and CFTR F508del mutation. Methods: A total of 19 patients with CF and 31 healthy control subjects completed an assessment of Q (C 2 H 2 rebreathing), SV (calculated from Q and heart rate [HR]), Q and SV indexed to body surface area (BSA, QI, and SVI, respectively), SVR (through assessment of Q and mean arterial blood pressure [MAP]), and HR (from 12-lead electrocardiogram [ECG]) at rest along with plasma measures of EPI and NE. We compared subjects by variables of cardiovascular function relative to EPI and NE, and also based on genetic variants of the F508del mutation (homozygous deletion for F508del, heterozygous deletion for F508del, or no deletion of F508del). Results: Cystic fibrosis patients demonstrated significantly lower BSA (CF = 1.71 ± 0.05 m 2 vs healthy = 1.84 ± 0.04 m 2 , P = .03) and SVI (CF = 30.6 ± 2.5 mL/beat/m 2 vs healthy = 39.9 ± 2.5 mL/beat/m 2 , P = .02) when compared with healthy subjects. Cystic fibrosis patients also demonstrated lower Q (CF = 4.58 ± 0.36 L/min vs healthy = 5.71 ± 0.32 L/min, P = .03) and SV (CF = 54 ± 5.5 mL/beat vs healthy = 73.3 ± 4.5 mL/beat, P = .01), and a higher HR (CF = 93.2 ± 3.9 bpm vs healthy = 80.5 ± 2.7 bpm, P < .01) and SVR (CF = 2082 ± 156 dynes*s/cm −5 vs healthy = 1616 ± 74 dynes*s/cm −5 , P = .01) compared with healthy subjects. Furthermore, CF patients demonstrated a lower SV ( P < .01) corrected for NE when compared with healthy subjects. No significant differences were seen in HR or Q relative to NE, or SVR relative to EPI. Differences were seen in SV (F (2,14) = 7.982, P < .01) and SV index (F (2,14) = 2.913, P = .08) when patients with CF were stratified according to F508del mutation (number of deletions). Conclusions: Individuals with CF have lower cardiac and peripheral hemodynamic function parameters at rest. Furthermore, these results suggest that impairment in cardiovascular function is likely the result of F508del CFTR genotype, rather than receptor desensitization or inhibited drug delivery.
The Effects of Racism in Medical Education on Students’ Decisions to Practice in Underserved or Minority Communities
Burke, Sara E. , Cunningham, Brooke A. , Perry, Sylvia , White, Richard O. , Yeazel, Mark W. , Onyeador, Ivuoma N. , Wittlin, Natalie M. , Harden, Kristin, Ryn, Michelle van , Phelan, Sean M. , Fischer, Kristin , Perry, Sylvia P , van Ryn, Michelle , Hardeman, Rachel R. , Dovidio, John F. , Herrin, Jeph , Dyrbye, Liselotte N.

Mayo Clinic

Academic Medicine | March 28, 2019 | Volume: 94 | Issue: 8 | Pages: 1178-1189

10.1097/acm.0000000000002719 | PMID 30920443 Get It

Purpose The purpose of this study was to examine the relationship between manifestations of racism in medical school and subsequent changes in graduating medical students’ intentions to practice in underserved or minority communities, compared with their attitudes and intentions at matriculation. Method The authors used repeated-measures data from a longitudinal study of 3,756 students at 49 U.S. medical schools that were collected from 2010 to 2014. They conducted generalized linear mixed models to estimate whether manifestations of racism in school curricula/policies, school culture/climate, or student attitudes/behaviors predicted first- to fourth-year changes in students’ intentions to practice in underserved communities or primarily with minority populations. Analyses were stratified by students’ practice intentions (no/undecided/yes) at matriculation. Results Students’ more negative explicit racial attitudes were associated with decreased intention to practice with underserved or minority populations at graduation. Service learning experiences and a curriculum focused on improving minority health were associated with increased intention to practice in underserved communities. A curriculum focused on minority health/disparities, students’ perceived skill at developing relationships with minority patients, the proportion of minority students at the school, and the perception of a tense interracial environment were all associated with increased intention to care for minority patients. Conclusions This study provides evidence that racism manifested at multiple levels in medical schools was associated with graduating students’ decisions to provide care in high-need communities. Strategies to identify and eliminate structural racism and its manifestations in medical school are needed.
Senescent cells in the development of cardiometabolic disease
Postmus, Andrea C. , Sturmlechner, Ines , Jonker, Johan W. , Deursen, Jan M. van , Sluis, Bart van de , Kruit, Janine K. , van de Sluis, Bart , Sturmlechner, Ines , Jonker, Johan W

Mayo Clinic

Current Opinion in Lipidology | March 26, 2019 | Volume: 30 | Issue: 3 | Pages: 177-185

10.1097/mol.0000000000000602 | PMID 30913069 Get It

Purpose of review Senescent cells have recently been identified as key players in the development of metabolic dysfunction. In this review, we will highlight recent developments in this field and discuss the concept of targeting these cells to prevent or treat cardiometabolic diseases. Recent findings Evidence is accumulating that cellular senescence contributes to adipose tissue dysfunction, presumably through induction of low-grade inflammation and inhibition of adipogenic differentiation leading to insulin resistance and dyslipidaemia. Senescent cells modulate their surroundings through their bioactive secretome and only a relatively small number of senescent cells is sufficient to cause persistent physical dysfunction even in young mice. Proof-of-principle studies showed that selective elimination of senescent cells can prevent or delay the development of cardiometabolic diseases in mice. Summary The metabolic consequences of senescent cell accumulation in various tissues are now unravelling and point to new therapeutic opportunities for the treatment of cardiometabolic diseases.
Targeting senescent cells alleviates obesity‐induced metabolic dysfunction
Xu, Ming , Zhu, Yi , Pirtskhalava, Tamar , Weivoda, Megan , Hachfeld, Christine, Prata, Larissa , Dijk, Theo H. van , Verkade, Esther, Casaclang‐Verzosa, Grace , Johnson, Kurt O. , Čubro, Hajrunisa, Doornebal, Ewald J. , Ogrodnik, Mikołaj , Jurk, Diana , Jensen, Michael D. , Chini, Eduardo N. , Miller, Jordan D. , Matveyenko, Aleksey V. , Schafer, Marissa , White, Thomas A. , Hickson, LaTonya J. , Demaria, Marco , Grande, Joseph P. , Kuipers, Folkert , Zglinicki, Thomas von , Campisi, Judith , Kirkland, James L. , Palmer, Allyson K. , Weivoda, Megan M, Hachfeld, Christine M, Prata, Larissa G, Casaclang-Verzosa, Grace, Matveyenko, Aleksey, Stout, Michael B, Schafer, Marissa J, Garovic, Vesna, Grande, Joseph, Hickson, LaTonya J , Xu, Ming , Jurk, Diana , Prata, Larissa G P Langhi , Schafer, Marissa J , Stout, Michael B , Garovic, Vesna D. , Arriaga, Edgar A. , LeBrasseur, Nathan K. , Tchkonia, Tamar , Zhu, Yi , Miller, Jordan

Mayo Clinic

Aging Cell | March 25, 2019 | Volume: 18 | Issue: 3 | Pages: No page available

10.1111/acel.12950 | PMID 30907060 Get It

Abstract Adipose tissue inflammation and dysfunction are associated with obesity‐related insulin resistance and diabetes, but mechanisms underlying this relationship are unclear. Although senescent cells accumulate in adipose tissue of obese humans and rodents, a direct pathogenic role for these cells in the development of diabetes remains to be demonstrated. Here, we show that reducing senescent cell burden in obese mice, either by activating drug‐inducible “suicide” genes driven by the p16 Ink4a promoter or by treatment with senolytic agents, alleviates metabolic and adipose tissue dysfunction. These senolytic interventions improved glucose tolerance, enhanced insulin sensitivity, lowered circulating inflammatory mediators, and promoted adipogenesis in obese mice. Elimination of senescent cells also prevented the migration of transplanted monocytes into intra‐abdominal adipose tissue and reduced the number of macrophages in this tissue. In addition, microalbuminuria, renal podocyte function, and cardiac diastolic function improved with senolytic therapy. Our results implicate cellular senescence as a causal factor in obesity‐related inflammation and metabolic derangements and show that emerging senolytic agents hold promise for treating obesity‐related metabolic dysfunction and its complications.